Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targacept Receives Grant From Michael J Fox Foundation
Targacept has received a grant of over $600,000 from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant, awarded as part of MJFF’s Therapeutics Development, is
Targacept has received a grant of over $600,000 from The Michael J Fox Foundation for Parkinson’s Research (MJFF). The grant, awarded as part of MJFF’s Therapeutics Development, is
Galapagos has received a milestone payment of E2.5 million in its osteoporosis collaboration with Eli Lilly. Reportedly, in December 2007, Lilly and Galapagos initiated an alliance to
Peplin has initiated the second non-head phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel, for the treatment of actinic keratoses (AK).
Repros Therapeutics has provided a clarification on the occurrence of increased liver enzymes in patients treated with the 50mg dose of Proellex. Repros’ recent decision to discontinue the
Bristol-Myers Squibb has reported net sales of $5.34 billion for the second quarter of 2009, as compared to $5.2 billion during the previous year. This represented an increase
Seattle Genetics has reported revenues in the second quarter of 2009 as $9.4 million, compared to $10 million in the second quarter of 2008. For the first six
Columbia Laboratories has signed an agreement with PharmaBio under which Columbia can extend its final royalty payment on sales of STRIANT from November 2010 to November 2011. The
EnteroMedics has reported a net loss of $10.4 million, or $0.34 per share, for the three months ended June 2009. For the six months ended June 2009, the
Aradigm has received clearance from the FDA for phase IIb clinical trial of its inhaled liposomal ciprofloxacin’s Investigational New Drug (IND) application. The study is a randomized, double-blind,
FDA has approved Allergan’s ACUVAIL (ketorolac tromethamine ophthalmic solution) 0.45%, a preservative-free formulation of ketorolac. Its a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and